WuXi Advanced Therapies Archives · BioBuzz

WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware

<img width="300" height="300" src="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/08/wuxi-groundbreaking-300x300.jpeg?lossy=1&strip=1&webp=1" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image" alt="" decoding="async" srcset="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/08/wuxi-groundbreaking-scaled-75x75.jpeg?lossy=1&strip=1&webp=1 75w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/08/wuxi-groundbreaking-150x150.jpeg?lossy=1&strip=1&webp=1 150w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/08/wuxi-groundbreaking.jpeg?size=240x240&lossy=1&strip=1&webp=1 240w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/08/wuxi-groundbreaking-300x300.jpeg?lossy=1&strip=1&webp=1 300w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : August 17, 2022September 2, 2022 Published by : BioBuzz Media

WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware. First announced in June 2021, this site will be WuXi STA’s second facility in the United States, offering expanded capacity and greater flexibility to meet the needs of customers in the U.S. and around the world.

WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies USA

<img width="300" height="300" src="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2020/11/WuXi-Advanced-Therapies-300x300.jpg?lossy=1&strip=1&webp=1" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2020/11/WuXi-Advanced-Therapies-75x75.jpg?lossy=1&strip=1&webp=1 75w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2020/11/WuXi-Advanced-Therapies-150x150.jpg?lossy=1&strip=1&webp=1 150w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2020/11/WuXi-Advanced-Therapies.jpg?size=240x240&lossy=1&strip=1&webp=1 240w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2020/11/WuXi-Advanced-Therapies-300x300.jpg?lossy=1&strip=1&webp=1 300w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : June 23, 2022June 23, 2022 Published by : BioBuzz Media

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen’s WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy product to cancer patients.

Philadelphia Real Estate Round-Up 2021

Image showing various photos of Philadelphia, with text saying "Philadelphia Real Estate Roundup"

<img width="300" height="300" src="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/01/MD-and-PA-Real-Esate-300x300.png?lossy=1&strip=1&webp=1" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image" alt="Image showing various photos of Philadelphia, with text saying "Philadelphia Real Estate Roundup"" decoding="async" loading="lazy" srcset="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/01/MD-and-PA-Real-Esate-75x75.png?lossy=1&strip=1&webp=1 75w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/01/MD-and-PA-Real-Esate-150x150.png?lossy=1&strip=1&webp=1 150w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/01/MD-and-PA-Real-Esate.png?size=240x240&lossy=1&strip=1&webp=1 240w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2022/01/MD-and-PA-Real-Esate-300x300.png?lossy=1&strip=1&webp=1 300w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : January 18, 2022January 18, 2022 Published by : Erika Riley

In 2021, Philadelphia continued to prove why it’s an up-and-coming life sciences and biotech cluster. Current reports state the city received $1.23 billion in National Institute of Health (NIH) funding in 2021 — and that number is expected to be bigger once finalized, said Lauren Gilchrist, Managing Director of Research at Longfellow Real Estate Partners.

Regional Collaborations Emerge to Address the Biomanufacturing Workforce Crisis

<img width="300" height="300" src="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/06/Biomanufacturing-Workforce-featured-img-300x300.png?lossy=1&strip=1&webp=1" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/06/Biomanufacturing-Workforce-featured-img-75x75.png?lossy=1&strip=1&webp=1 75w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/06/Biomanufacturing-Workforce-featured-img-150x150.png?lossy=1&strip=1&webp=1 150w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/06/Biomanufacturing-Workforce-featured-img.png?size=240x240&lossy=1&strip=1&webp=1 240w, https://b2193782.smushcdn.com/2193782/wp-content/uploads/2021/06/Biomanufacturing-Workforce-featured-img-300x300.png?lossy=1&strip=1&webp=1 300w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : June 22, 2021June 22, 2021 Published by : Steven Surdez

We have been covering the biomanufacturing workforce at length this year because it remains one of the most important topics for companies in today’s near full-employment job market.